Literature DB >> 22367391

First case report of a peripheral T-cell lymphoma, not otherwise specified, of the central nervous system in a child.

Maria Lueth1, Harald Stein, Birgit Spors, Guenter Henze, Pablo Hernáiz Driever.   

Abstract

We report on the first pediatric patient with a localized primary peripheral T-cell lymphoma, not otherwise specified, of the central nervous system (CNS). The solid lesion that was enhanced in magnetic resonance images of the left precentral region was totally resected. The histopathology revealed a peripheral T-cell lymphoma, not otherwise specified. Staging procedures showed that the lesion was confined to the CNS. Without any further therapy, the patient still remains in complete remission 6 years after diagnosis. Thus, we conclude that a peripheral T-cell lymphoma, not otherwise specified, of the CNS can occur in children. In the case presented here, complete resection sufficed.

Entities:  

Mesh:

Year:  2012        PMID: 22367391     DOI: 10.1097/MPH.0b013e318219f95e

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

1.  Primary CNS T-cell Lymphomas: A Clinical, Morphologic, Immunophenotypic, and Molecular Analysis.

Authors:  Madhu P Menon; Alina Nicolae; Hillary Meeker; Mark Raffeld; Liqiang Xi; Armin G Jegalian; Douglas C Miller; Stefania Pittaluga; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2015-12       Impact factor: 6.394

Review 2.  Primary T cell central nervous system lymphoblastic lymphoma in a child: case report and literature review.

Authors:  Marcus D Mazur; Vijay M Ravindra; Mouied Alashari; Elizabeth Raetz; Matthew M Poppe; Robert J Bollo
Journal:  Childs Nerv Syst       Date:  2015-02-15       Impact factor: 1.475

3.  Prolonged Complete Response in a Pediatric Patient With Primary Peripheral T-Cell Lymphoma of the Central Nervous System.

Authors:  Haneen Shalabi; Anne Angiolillo; Gilbert Vezina; James L Rubenstein; Stefania Pittaluga; Mark Raffeld; Leigh Marcus
Journal:  Pediatr Hematol Oncol       Date:  2015-09-18       Impact factor: 1.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.